News from novartis pharmaceuticals corporation A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Dec 16, 2014, 08:00 ET

Novartis gains FDA approval for Signifor® LAR to treat patients with acromegaly, a rare and life-threatening hormonal disorder

 Novartis announced today that the US Food and Drug Administration (FDA) has approved Signifor® long-acting release (LAR)* (pasireotide)...

Dec 09, 2014, 13:37 ET

Novartis highlights new CTL019 clinical data showing complete remissions in children and young adults with relapsed/refractory acute lymphoblastic leukemia

 Findings from continued clinical studies of investigational chimeric antigen receptor (CAR) therapy, CTL019, demonstrate its potential role in...

Dec 02, 2014, 01:15 ET

Novartis features innovative immunotherapy, targeted pipeline treatment combinations and long-term data at ASH and SABCS 2014

 Novartis will highlight more than 250 abstracts demonstrating advances in blood and breast cancer research at the upcoming American Society of...

Nov 17, 2014, 16:47 ET

Nine new analyses show Novartis' LCZ696 could change course of heart failure for patients

 New data on Novartis' investigational medicine, LCZ696, for patients with heart failure with reduced ejection fraction (HFrEF) shows it has...

Nov 16, 2014, 14:37 ET

Novartis first IL-17A Phase III results show AIN457 (secukinumab) significantly improves psoriatic arthritis in patients

    Novartis announced today results from the pivotal Phase III FUTURE 1 and FUTURE 2 studies showing AIN457...

Nov 15, 2014, 16:50 ET

Novartis AIN457 (secukinumab) showed significant symptom improvement in two pivotal Phase III ankylosing spondylitis studies

 Novartis announced today results from the MEASURE 1 and MEASURE 2 pivotal Phase III studies of AIN457 (secukinumab) in ankylosing spondylitis...

Nov 10, 2014, 07:00 ET

Novartis to present first IL-17A Phase III data for AIN457 (secukinumab) in psoriatic arthritis and ankylosing spondylitis at ACR 2014

 Novartis announced today that data from two pivotal Phase III studies (FUTURE 1 and FUTURE 2) in psoriatic arthritis (PsA) patients and two...

Nov 03, 2014, 09:00 ET

US results from first global survey of neuroendocrine tumor (NET) patients reveal profound impact of this rare cancer on quality of life

 Novartis together with the Carcinoid Cancer Foundation and the Caring for Carcinoid Foundation, member organizations of the International...

Oct 21, 2014, 07:00 ET
Photo Caption: David Osmond, music artist, producer, MS advocate

Novartis teams up with multiple sclerosis advocate and musician David Osmond to launch MS education initiative Our Voice in Song™

Today Novartis Pharmaceuticals Corporation launched a new multifaceted multiple sclerosis (MS) awareness campaign aimed to motivate people with...

Oct 20, 2014, 15:10 ET

Novartis announces FDA Advisory Committee unanimously recommends approval of AIN457 (secukinumab) for patients with moderate-to-severe plaque psoriasis

 Novartis announced the Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) to the US Food and Drug Administration (FDA) today...

Aug 30, 2014, 07:03 ET

Novartis' new heart failure medicine LCZ696 cut cardiovascular deaths by 20% vs. ACE-inhibitor in landmark PARADIGM-HF trial

 Today at the European Society of Cardiology congress and published simultaneously in the New England Journal of Medicine, Novartis revealed...

Aug 11, 2014, 01:18 ET

Novartis to showcase heart failure leadership at ESC Congress 2014 with results on new first of its type medicine LCZ696

 New data revealing the reduction in cardiovascular (CV) deaths with Novartis' LCZ696 in patients with heart failure with reduced ejection...

Jun 01, 2014, 09:02 ET

Pivotal data for Novartis' investigational compound LDE225 show marked tumor responses in advanced basal cell carcinoma

Novartis announced today the results of a pivotal Phase II trial demonstrating that patients with locally advanced (laBCC) or metastatic basal cell...

May 05, 2014, 01:21 ET

Novartis drug Signifor® LAR shows superior efficacy in acromegaly patients not controlled on first generation somatostatin analogues

 Novartis today presented results from a pivotal Phase III trial of investigational therapy Signifor® LAR (pasireotide LAR; SOM230) in...

Apr 23, 2014, 06:15 ET

Novartis recognized as top ranking company in the US on DiversityInc Top 50 Companies for Diversity list

 Novartis Pharmaceuticals Corporation (NPC) has been named the leading company on the 14th annual DiversityInc Top 50 Companies for Diversity...

Apr 03, 2014, 07:00 ET

Novartis data on 19 compounds at AACR highlight strong cancer pipeline across multiple molecular targets and biological pathways

 Novartis announced today that early stage data on 19 investigational compounds in its oncology pipeline will be presented at the annual...

Mar 22, 2014, 08:00 ET

Novartis reports new Phase III data showing secukinumab (AIN457) improved moderate-to-severe plaque psoriasis in patients

 Novartis today announced results from the Phase III FEATURE and JUNCTURE studies showing secukinumab (AIN457), a selective interleukin-17A...

Mar 21, 2014, 14:58 ET

Novartis Announces FDA Approval of Xolair® (omalizumab) for Chronic Idiopathic Urticaria (CIU), a Form of Chronic Hives

Novartis today announced that the US Food and Drug Administration (FDA) approved Xolair® (omalizumab) for the treatment of chronic idiopathic...

Jan 08, 2014, 18:50 ET

Novartis Pharmaceuticals Corporation stands behind medication adherence activities and reaffirms commitment to patient safety

 Patient safety and well-being are the highest priority at Novartis Pharmaceuticals Corporation (NPC). NPC is dedicated to improving patient...

Jun 04, 2013, 08:00 ET
Join Phil Keoghan and Novartis to raise awareness of MS. www.TogetherinMS.com.  (PRNewsFoto/Novartis Pharmaceuticals Corporation)

TV Host Phil Keoghan and Novartis team up to inspire people with MS through innovative tandem cycling campaign

Phil Keoghan, host of "The Amazing Race" and founder of No Opportunity Wasted (NOW), joins Novartis Pharmaceuticals Corporation for the third year...